DRG Epidemiology's coverage of irritable bowel syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of irritable bowel syndrome for each country as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.
DRG Epidemiology's irritable bowel syndrome forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of irritable bowel syndrome over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following irritable bowel syndrome subpopulations:
IBS prevalent cases by predominant symptom status.
Prevalence of Irritable Bowel Syndrome per 100 Among Those Aged 20 or Older in 2018 and 2038
Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Irritable Bowel Syndrome Over the Next 20 Years
Analysis of the Prevalent Cases of Irritable Bowel Syndrome in 2018 by IBS Subtypes
Epidemiology Data
Methods
Total Prevalent Cases
IBS Subtypes
Reference Materials
Literature Review
Studies Included in the Analysis of Irritable Bowel Syndrome
Studies Excluded from the Analysis of Irritable Bowel Syndrome
Risk/Protective Factors
Risk/Protective Factors for Irritable Bowel Syndrome
Bibliography
Shilpa Thakur
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.
Abey John, M.P.H.
Abey John, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing family planning health programs in India in collaboration with the government of India. He also has worked at the grassroots level as a health team manager to help the rural population living in the foothills of the Himalayas. He holds a master’s degree in public health.
